Datasheet for ABIN967507

anti-CDKN1C antibody

2 Images | 3 Publications

Go to Product page

Overview

Quantity:	0.1 mg
Target:	CDKN1C
Reactivity:	Human
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This CDKN1C antibody is un-conjugated
Application:	Western Blotting (WB)

Product Details

Brand:	BD Pharmingen™
Immunogen:	p57[Kip2] Recombinant Human
Clone:	A120-1
Isotype:	IgG1 kappa
Characteristics:	1. Since applications vary, each investigator should titrate the reagent to obtain optimal results. 2. Please refer to us for technical protocols. 3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
Purification:	The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Target Details

Target:	CDKN1C
Alternative Name:	p57 Kip2 (CDKN1C Products)
Background:	Cyclin dependent kinase inhibitors (CdkIs) inhibit progression through the cell cycle by binding to cyclins, Cdks, or cyclin-Cdk complexes. CdkIs are classified into two groups based on protein structure. p57[Kip2] belongs to a group that also includes p27[Kip1] and p21 (also known as Sdi1, Cip1, Waf1 and Pic1). Members of this group have a homologous amino-terminal Cdk inhibitory domain. Members of the second group [p16 (INK4A), p15 (INK4B), p18 (INK4C), and p19 (INK4D)] contain ankyrin repeat motifs. p57[Kip2] is a potent, tight-binding inhibitor of several G1 and S phase cyclin-Cdk complexes including cyclin E-Cdk2, cyclin D2-Cdk4, and cyclin A-Cdk2. It inhibits the mitotic cyclin B1-Cdk1 complex to a lesser extent. mRNA studies suggest that p57[Kip2] expression is tissue-specific, the highest levels have been found in embryonic and adult skeletal muscle, heart, kidney, lung, eye and brain. This is in contrast to the widespread tissue expression of p27[Kip1] and p21 mRNA. The expression of p57[Kip2] to primarily terminally differentiated cells suggests that p57[Kip2] may play a specialized role in cell cycle control. Clone A120-1 reacts with human p57[Kip2]. Recombinant human p57[Kip2] was used as immunogen.
Molecular Weight:	57 kDa
Pathways:	Cell Division Cycle, Dopaminergic Neurogenesis

Application Details

Application Notes:	Applications for clone A120-1 include western blot analysis (1-2 µg/ml). SJCRH30 human rhabdomyosarcoma cells are suggested as a positive control (ATCC CRL-2061).
Comment:	Related Products: ABIN967389
Restrictions:	For Research Use only

Handling

Format:	Liquid
Concentration:	0.5 mg/mL
Buffer:	Aqueous buffered solution containing ≤0.09 % sodium azide.
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which

Handling

	should be handled by trained staff only.
Storage:	4 °C
Storage Comment:	Store undiluted at 4°C.

Publications

Product cited in:	Graña, Reddy: "Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)." in: **Oncogene**, Vol. 11, Issue 2, pp. 211-9, (1995) (PubMed). Lee, Reynisdóttir, Massagué: "Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution." in: **Genes & development**, Vol. 9, Issue 6, pp. 639-49, (1995) (PubMed). Matsuoka, Edwards, Bai, Parker, Zhang, Baldini, Harper, Elledge: "p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene." in: **Genes & development**, Vol. 9, Issue 6, pp. 650-62, (1995) (PubMed).

Images

Image 1.



Western Blotting

Image 2. Western blot analysis of p57[Kip2]. Lane 1, SJCRH30 human rhabdomyosarcoma cell lysate was probed with anti-p57[Kip2]. In lane 2, mouse IgG1 isotype (negative) control. p57[Kip2] is identified as an ~57 kDa doublet.